Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis
Frank Weinz, DVT Spezialist at Arjo, shared on LinkedIn:
”State-of-the-art thromboembolism prophylaxis with the IPK Flowtron ACS900 system from Arjo!
The Flowtron ACS900 is a sophisticated system for VTE (venous thromboembolism) prophylaxis that provides compression therapy to improve blood circulation and prevent thrombosis in clinical settings.
It provides a safe, efficient, and measurable solution for patient treatment—a key aspect in reducing complications such as perioperative thrombosis.
Patient safety
The Flowtron ACS900 uses controlled and intermittent compression to reduce the risk of blood clots.
It is designed so that compression applied to the extremities from distal to proximal with an optimal pressure gradient exerts optimal pressure, thereby significantly minimizing the risk of thrombosis.
This is particularly important in the operating room setting, where patients lie still for long periods of time and the risk of thrombosis and pulmonary embolism is higher.
Compliance
A key feature of the Flowtron ACS900 is that it promotes compliance among both patients and medical staff.
The easy-to-use devices ensure that the therapy is applied regularly and correctly.
Clinical practice has shown that the surgical team appreciates this system thanks to its user-friendliness and effectiveness, which leads to improved therapeutic success.
Measurability and clinical effectiveness
A key advantage of the Flowtron ACS900 compared to other systems, such as the SCD 700, is the ability to directly monitor and document the therapy and its application.
The device provides measurability of compression therapy, allowing medical staff to clearly understand the effectiveness of the treatment.
Efficiency in the operating room
The Flowtron ACS900 from Arjo enables optimized treatment during surgery. Intermittent pneumatic compression increases venous return of venous blood, significantly reducing the risk of stasis.
The Flowtron ACS900 takes over complete thrombosis prophylaxis during use. This reduces the workload for nursing staff, leading to greater efficiency and more effective work in everyday clinical practice.
Evidence-based VTE prevention
The Flowtron ACS900 is based on evidence-based studies that confirm its effectiveness in preventing VTE.
This means that it is not only a functional system for everyday clinical use, but also a device that can demonstrate scientifically proven results, thereby inspiring confidence among doctors and nursing staff.
The Flowtron ACS900 from Arjo offers a state-of-the-art solution for efficient VTE prophylaxis.
It promotes patient safety, ensures compliance during use, and enables measurable, clinically proven therapy.”
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:45Khurram Nasir on Where The Cholesterol Guidelines Are Headed
-
Jan 12, 2026, 01:35Nirav Dhanesha Shares The Lab’s Latest Publication on Neutrophil CD14 and DVT Link
-
Jan 12, 2026, 01:30Exploring the Grey Zone of Subacute Coronary Artery Occlusion
-
Jan 12, 2026, 01:07Akshat Jain Presents The New Edition of Global Sickle Cell Disease Insight Publication